Wellpoint’s agency well-visit
This article was originally published in The Tan Sheet
Executive Summary
FDA still is "actively working on" Wellpoint Health Network's petition to forcibly switch all low- and non-sedating antihistamines from prescription status, FDA promises the insurer in an Aug. 5 letter. Wellpoint urged Acting FDA Commissioner Lester Crawford, PhD, to reply to its 1998 and 2000 petitions to switch Pfizer's Zyrtec, Schering-Plough's Clarinex and Aventis' Allegra over the counter in a recent letter (1"The Tan Sheet" July 26, 2004, p. 6)...
You may also be interested in...
Antihistamine Price Erosion Justifies Forced Switch – WellPoint
WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.